ANBT
TVTX icon

American National Bank & Trust’s Travere Therapeutics TVTX Stock Holding History

American National Bank & Trust’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$359 – 763
2025
Q3 		$359 Hold
15
– – ﹤0.01% 631
2025
Q2 		$222 Buy
+15
New +$249 ﹤0.01% 639

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American National Bank & Trust's TVTX Position: Q4 2025 in Review

American National Bank & Trust sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 15 shares — an estimated $359 sold.

American National Bank & Trust first reported a position in TVTX in Q2 2025 and held it in 2 quarters. The position peaked at $359 in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • American National Bank & Trust reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • American National Bank & Trust sold 15 Travere Therapeutics shares in Q4 2025, an estimated $359.
  • American National Bank & Trust first reported a position in Travere Therapeutics in Q2 2025 and held it in 2 quarters.
  • American National Bank & Trust's Travere Therapeutics position peaked at $359 in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on American National Bank & Trust's 13F filing for Q4 2025, filed 20 Jan 2026.